About This Trial

Radioligand therapy combined with pembrolizumab for enhanced tumor killing.

Primary Endpoints

  • Overall survival
  • Radiographic progression-free survival

Latest Update

February 2026

Interim analysis triggered early. Results expected Q2 2026 with potential accelerated approval pathway.